


## SIRT2-IN-8

<b>Cat. No.:</b>	HY-107660
<b>CAS No.:</b>	115687-05-3
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>17</sub> ClN <sub>4</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	396.83
<b>Target:</b>	Sirtuin
<b>Pathway:</b>	Cell Cycle/DNA Damage; Epigenetics
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 50 mg/mL (126.00 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.5200 mL	12.5999 mL	25.1997 mL
5 mM	0.5040 mL	2.5200 mL	5.0399 mL
10 mM	0.2520 mL	1.2600 mL	2.5200 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

SIRT2-IN-8 is a potent SIRT2 inhibitor. SIRT2-IN-8 can be used for Huntington's and Parkinson's diseases research<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

SIRT2

### REFERENCES

[1]. Bodner RA, Outeiro TF, Altmann S, et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A. 2006;103(11):4246-4251.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA